Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study

SH Khoo, R Fitzgerald, T Fletcher… - Journal of …, 2021 - academic.oup.com
Objectives AGILE is a Phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In
this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in …
被引用次数：131 相关文章

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study

SH Khoo, R Fitzgerald, T Fletcher… - Journal of …, 2021 - archive.lstmed.ac.uk
Objectives AGILE is a Phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In
this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in …

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study.

SH Khoo, R Fitzgerald, T Fletcher, S Ewings… - The Journal of …, 2021 - europepmc.org
Objectives AGILE is a Phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In
this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in …

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study

SH Khoo, R Fitzgerald, T Fletcher, S Ewings, T Jaki… - 2021 - pubmed.ncbi.nlm.nih.gov
Objectives AGILE is a Phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In
this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in …
[HTML] nih.gov

[HTML][HTML] Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study

SH Khoo, R Fitzgerald, T Fletcher… - Journal of …, 2021 - ncbi.nlm.nih.gov
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label,
dose-escalating, randomized controlled study - PMC Back to Top Skip to main content NIH …

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study

SH Khoo, R Fitzgerald, T Fletcher, S Ewings… - Journal of Antimicrobial …, 2021 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title> Objectives</jats: title>< jats: p>
AGILE is a Phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In this trial …
[PDF] oup.com

[PDF][PDF] Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study

SH Khoo, R Fitzgerald, T Fletcher… - Journal of …, 2021 - academic.oup.com
Objectives AGILE is a Phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In
this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in …

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study

SH Khoo, R Fitzgerald, T Fletcher… - Journal of …, 2021 - eprints.soton.ac.uk
Objectives: AGILE is a Phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In
this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in …

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study.

SH Khoo, R Fitzgerald, T Fletcher, S Ewings, T Jaki… - 2021 - cabidigitallibrary.org
Objectives: AGILE is a Phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In
this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in …

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase 1, dose-escalating, randomised controlled study

SH Khoo, R FitzGerald, T Fletcher, S Ewings, T Jaki… - medRxiv, 2021 - medrxiv.org
Background AGILE is a phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In
this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in …